Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Dendreon moves ahead with dendritic cell therapies for cancer

June 10, 1999

Maxamine plus IL-2 prolongs duration of complete remission in patients with AML

June 10, 1999

European Commission issues first approval for tasonermin

June 8, 1999

LifeTime and Dovetail enter exclusive agreement for Beta LT anticancer compound

June 8, 1999

AVI BioPharma to initiate phase II clinical trial of Avicine in pancreatic cancer

June 7, 1999

Additional phase II data suggest modifications for AVI BioPharma's cancer vaccine

June 1, 1999

Phase II trial of York Medical's cancer vaccine cleared

June 1, 1999

Ilex reports progress on Campath development at annual meeting

May 31, 1999

Encouraging phase I trials results for Prostvac presented at ASCO

May 27, 1999

Antiidiotype cancer vaccine induces immune response and may delay disease progression in MBC

May 27, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...